Harvard Bioscience (NASDAQ:HBIO) Director Acquires $48,700.00 in Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Director Stephen Denelsky acquired 10,000 shares of Harvard Bioscience stock in a transaction on Tuesday, March 17th. The stock was acquired at an average cost of $4.87 per share, for a total transaction of $48,700.00. Following the completion of the purchase, the director owned 21,000 shares of the company’s stock, valued at approximately $102,270. The trade was a 90.91% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Harvard Bioscience Price Performance

HBIO opened at $5.27 on Friday. The company has a fifty day moving average price of $5.55 and a two-hundred day moving average price of $5.66. The firm has a market capitalization of $23.56 million, a PE ratio of -0.41 and a beta of 1.51. Harvard Bioscience, Inc. has a 52 week low of $2.81 and a 52 week high of $9.50. The company has a debt-to-equity ratio of 2.61, a quick ratio of 0.41 and a current ratio of 2.20.

Hedge Funds Weigh In On Harvard Bioscience

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its position in Harvard Bioscience by 44.4% in the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 11,948 shares during the last quarter. Geode Capital Management LLC boosted its position in Harvard Bioscience by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 460,793 shares of the medical instruments supplier’s stock worth $308,000 after acquiring an additional 18,923 shares during the last quarter. Legato Capital Management LLC boosted its position in Harvard Bioscience by 210.4% during the 4th quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 29,462 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Harvard Bioscience by 291.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 37,057 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Harvard Bioscience during the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. Wall Street Zen lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday. New Street Research set a $6.00 target price on Harvard Bioscience in a report on Friday, March 13th. Zacks Research upgraded Harvard Bioscience to a “hold” rating in a research report on Thursday, December 11th. Finally, Benchmark lowered their price target on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a research note on Friday, March 13th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $6.00.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.